Johnson & Johnson reported declines in sales and earnings due to generic competition and unfavorable currency impacts. Delays in key drug approvals and increased pricing pressures in the medical devices segment add to short-term concerns. While cost management is strong and guidance is maintained, these negative factors are likely to pressure the stock price in the coming weeks.

[-1]